Dopamine agonists (Q33545297)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Dopamine agonists	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

Europe PubMed Central

Dopamine agonists. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

0 references

author name string

Factor SA

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

publication date

1 March 1999

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Medical Clinics of North America

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

83

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

415-43, vi-vii

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Levodopa: is toxicity a myth?

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Adverse reactions to levodopa: drug toxicity or progression of disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Treatment of Parkinson's disease with pergolide: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Pergolide: long-term use in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Pleuropulmonary disease associated with dopamine agonist therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

The free radical hypothesis in idiopathic parkinsonism: evidence against it

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Subcutaneous apomorphine for on-off oscillations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Double-blind trial of pergolide for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Early combination therapy with bromocriptine and levodopa in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

The oxidant stress hypothesis in Parkinson's disease: evidence supporting it

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

[Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study]

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Subcutaneous apomorphine in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

The effect of bromocriptine (BCT) on the on-off phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Agonist substitution in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Pramipexole in patients with early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Controlled study of the antiparkinsonian activity and tolerability of cabergoline

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Long-term study of pergolide in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Long-term experience with pergolide therapy of advanced parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Cabergoline in Parkinson's disease: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Pergolide in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Final report

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Excitation of type II anterior caudate neurons by stimulation of dopamine D3 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Side-effects of subcutaneous apomorphine in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Combined bromocriptine-levodopa therapy early in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Early dopamine agonist therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

SIDE-EFFECTS OF SUBCUTANEOUS APOMORPHINE IN PARKINSON'S DISEASE

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Dopamine receptors in the basal ganglia: relevance to Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Pharmacologic profile of ropinirole: a nonergoline dopamine agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Ropinirole without levodopa in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

The role of dopamine agonists in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Dopamine agonists in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

Antioxidant properties of bromocriptine, a dopamine agonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970112-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0025-7125(05)70112-7

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33545297&oldid=1638126365"